After its foundation Exploris started out as a data analysis service company. In collaboration with the University Hospital in Basel we developed a novel, non-invasive AI test for timely detection of coronary artery disease. We set out to create solutions that will transform health-care. Exploris is one of the first companies having Artificial Intelligence based diagnostic and therapeutic solutions that have passed clinical studies.
Peter founded Exploris with the aim to enable a transformation in health care through AI-based diagnostic and therapeutic solutions. After his training as an engineer, he began his career in a Swiss industrial group and became CIO of the group. Then he made an MBO of an IT company and was co-owner of the Ruf Group. Peter is also member of the board of the Zürcher Kantonalbank.
After his executive MBA/HSG he focused on business development in the various fields of dentistry and medicine, including Cardio Explorer. He was involved in the international expansion of the Swiss Smile Dental Clinic group, business consulting of medical related industries and cloud-based medical and dental platform services.
Andrew has broad experience in data analysis and modeling through various projects in health-care and banking. He has extensive knowledge in applying innovative technologies for data analysis, development, optimization, validation and calibration of data classification models. Andrew and his team have been pioneers in realizing the whole process of data analysis and modeling in a holistic approach, resulting in the proprietary AI-X-platform.
Milica is an organized and mission-oriented Marketing and Communications specialist. She has a broad experience in working on connecting the client needs with the company's strategies and solutions. Milica is supporting the management and is responsible for Marketing (Social Media, Events, Promotions, Advertising) and various Projects.
Daniel has been engaged many years in various functions in Switzerland and abroad for a publicly listed Swiss company, last as CFO of the Group. He has comprehensive knowledge in financial management and developing business strategies as well as implementing efficiency improvement projects. Daniel is responsible for a major refinancing of the group and various company acquisitions.
Exploris and the cardiology department started to collect patient data in order to develop a model-based diagnostic solution for CAD diagnosis. Three prospective clinical studies have been successfully completed. Michael is responsible for the clinical development of the Cardio Explorer.
Hans-Peter is head of the division Structural Heart Diseases, the Heart Failure Clinic and a specialist in clinical research. Hans-Peter is lead partner of the joint EU Interreg project PASSION which develops a fundamental new therapy for heart failure. Hans-Peter leads the clinical development of the Heart Failure Explorer.
He is principal investigator of the German LURIC study and a specialist in epidemiology and genetics of cardio vascular disease. He is active in various international committees as an independent scientific advisor and deputy chairman of the D-A-C-H society for the prevention of cardiovascular diseases. Winfried März supports Exploris in laboratory related issues.
Exploris provides Artificial Intelligence based diagnostic and therapeutic lab tests, allowing for higher precision of results and increased convenience and safety for patients.
We enhance lab tests with Artificial Intelligence based predictive modeling for improved interpretation of lab results. The technology platform comprises clinical data sources, knowledge and a proprietary software engine which is capable of so far unmet capabilities in detecting new combinations of markers. A change in health status is reflected in physiological factors. Identifying the relevant factors and determining their relationship leads to new diagnostic approaches and improved therapies.
As a pioneer in Artificial Intelligence based eDiagnostics and eTherapeutics, we are one of the first companies which have successfully passed clinical studies for our novel, groundbreaking tests. Bringing the power of our extensive Artificial Intelligence software suite, the internet and the huge source of information in collected data together, turns out to be one of the most important technological advances in health care.
Swiss Biolabs Award
IFAS Innovation Challenge
Digital Health Forum